Showing 1801-1810 of 4063 results for "".
- Clearside Biomedical Completes Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-completes-dosing-in-cohort-2-of-phase-12a-clinical-trial-of-cls-ax-in-wet-amd-patients/2480292/Clearside Biomedical announced completion of dosing in Cohort 2 of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a U.S.-based, multicenter
- EyeGate Pharma Completes Target Enrollment in Phase 2 Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammationhttps://modernod.com/news/eyegate-pharma-completes-target-enrollment-in-phase-2-study-to-evaluate-pp-001-for-the-treatment-of-ocular-surface-inflammation/2479490/EyeGate Pharmaceuticals announced that it has completed target enrollment of 21 patients in the phase 2 proof-of-concept (POC) study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001
- Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trialhttps://modernod.com/news/nicoxs-ncx-470-demonstrates-significant-intraocular-pressure-lowering-in-dolomites-phase-2-glaucoma-trial/2479333/Nicox presented results from the Dolomites phase 2 clinical trial showing that NCX 470, a novel nitric oxide (NO)-donating prostaglandin analog (PGA), produced significantly greater IOP lowering effects in glaucoma patients compared with the current standard of care, latanoprost. In Dolom
- Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpointshttps://modernod.com/news/ocuphires-vega-1-phase-2-trial-in-presbyopia-meets-primary-and-secondary-endpoints/2479332/Ocuphire Pharma announced that the VEGA-1 phase 2 clinical trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects successfully met its primary and many secondary endpoints. On the strength of these results, Ocuphire plans to move in
- Oyster Point Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial for Patients with Neurotrophic Keratopathyhttps://modernod.com/news/oyster-point-announces-enrollment-of-first-subject-in-the-olympia-phase-2-clinical-trial-for-patients-with-neurotrophic-keratopathy/2479308/Oyster Point Pharma announced enrollment of the first subject in the OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray for the treatment of Stage 1 Neurotrophic Keratopathy (NK). “This is an exciting milestone as we continue to develop this potentially new tr
- EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Studyhttps://modernod.com/news/eyegate-pharma-announces-first-patient-dosed-for-pp-001-in-a-phase-2-proof-of-concept-ocular-surface-inflammation-study/2479289/EyeGate Pharmaceuticals announced the first patient dosed in phase 2 proof-of-concept study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001, an immune-modulating molecule, is an in
- Oxurion Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of DMEhttps://modernod.com/news/oxurion-completes-patient-enrollment-for-part-a-of-phase-2-study-evaluating-thr-149-for-treatment-of-dme/2479273/Oxurion NV announced the completion of patient enrollment into Part A of its two part phase 2 study (KALAHARI) evaluating multiple injections of THR-149 for the treatment of DME. Dose selection data from Part A of the study is expected in the second half of 2021. THR-149, Oxurion’s most ad
- Roche Receives FDA Authorization for Testing of Asymptomatic People With the Obas SARS-CoV-2 Testhttps://modernod.com/news/roche-receives-fda-authorization-for-testing-of-asymptomatic-people-with-the-obas-sars-cov-2-test/2479223/Roche announced that its cobas SARS-CoV-2 test for use on the widely available, high-throughput cobas 6800/8800 Systems has received Emergency Use Authorization (EUA) from the FDA for testing individuals without symptoms or reasons to suspect COVID-19. This authorization supports the guidance upd
- Biogen’s Phase 2/3 Gene Therapy Study for XLRP Fails to Meet Primary Endpointhttps://modernod.com/news/biogens-phase-2-3-gene-therapy-study-for-xlrp-fails-to-meet-primary-endpoint/2479216/Biogen announced topline results from the phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP). The XIRIUS study did not meet its primary endpoint of demonstrating a st
- Tarsus Pharmaceuticals Initiates Saturn-2 Phase 3 Trial Evaluating the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-initiates-saturn-2-phase-3-trial-evaluating-the-safety-and-efficacy-of-tp-03-for-the-treatment-of-demodex-blepharitis/2479179/Tarsus Pharmaceuticals announced that it has commenced enrollment in Saturn-2, its second pivotal trial evaluating the company’s novel investigational treatment, TP-03, in patients with Demodex blepharitis. Up to 25 million Americans may be affected by Demodex blepharitis, which is caused by an i